Metastatic Prostate Cancer: Current Trends and Future Landscape

Learning Objectives: At the completion of this activity, participants should be better able to: 1. Communicate with patients and colleagues about the pathophysiology, risk factors, symptoms, and genetics of prostate cancer. 2. Create individualized treatment plans for patients with prostate cancer based on current screening and staging guidelines and evidence for monotherapy, combination therapy, and sequencing of therapies. 3. Evaluate data for the benefits and risks of current an...
Applied Clinical Education

Occurrence and Implications of Chemotherapy-Induced Nausea and Vomiting (CINV)

Oncology nursing professionals play a key role in the care of patients receiving chemotherapy. However, to do so, they require access to the most recent clinical information and guidance, the latest developments in CINV therapy, and expanded knowledge of CINV pathophysiology. In addition, oncology nursing professionals need continuing education focused on appropriate screening in order to better identify patients at risk of CINV before chemotherapy begins, and developing the skills to undertak...
American Academy of CME

Immunotherapy: Harnessing the Immune System to Treat Cancer

This educational activity is directed toward oncology nurses and nurse practitioners caring for patients receiving cancer immunotherapy. Learning Objectives Upon completion of this activity, the participant will be able to: 1. List the various types of immunotherapy currently used in the management of malignancies 2. Summarize the various mechanisms of action for the different immunotherapy agents 3. Describe various toxicities for specific types of immunotherapy 4. Explain specific...
Medical Learning Institute

Patient-Centered Care of Metastatic Colon and Rectal Cancer

This educational activity is directed toward oncology nurses and nurse practitioners who have expressed a need for educational programming on the coordination of care, management of adverse events, counseling and education, and patient follow-up in metastatic colon and rectal cancer (mCRC). Such education would allow these healthcare professionals to take on leadership roles in the multi-disciplinary care of mCRC, leading to improved patient outcomes. Learning Objectives At the conclusion...
Medical Learning Institute

Hematology/Oncology PICU Issues: Case Studies

Learning Objectives: Review the importance of hemoglobin, coagulation, bone marrow, fibrinolytic and transfusion issues with the critically ill child. Describe the diagnostic laboratory data necessary to care for the child with anemia, platelet disorders, and oncologic emergencies. Prioritize the care for the child with an oncologic emergency.
Contemporary Forums

Update on Nursing Management of Cancer Therapy-Related Dermatologic Toxicities

STATEMENT OF NEED Many patients who receive novel targeted therapies and immunotherapies develop dermatologic toxicities that are associated with impaired quality of life due to sequelae such as pain, pruritus, and anxiety. The type and severity of dermatologic toxicity can vary significantly between classes of agents and pose distinct nursing management challenges in prophylaxis, treatment, and monitoring. For example, patients receiving EGFR inhibitors or immune-checkpoint inhibitors (eg,...
i3 Health

The Oncologist: A Prospective Multicenter Study Evaluating Secondary Adrenal Suppression After Antiemetic Dexamethasone Therapy in Cancer Patients Receiving Chemotherapy: A KSWOG Study

Learning Objectives: 1. Discuss the incidence associated with secondary adrenal suppression related to antiemetic dexamethasone therapy in cancer patients receiving chemotherapy. 2. Discuss the associated factors with secondary adrenal suppression related to antiemetic dexamethasone therapy in cancer patients receiving chemotherapy. 3. Describe the potential for adrenal insufficiency secondary to antiemetic dexamethasone therapy in cancer patients receiving chemotherapy.. Background. In...
Society For Translational Oncology

The Oncologist: Ramosetron Vs Ondansetron in Combination With Aprepitant and Dexamethasone for the Prevention of Highly Emetogenic Chemotherapy-Induced Nausea & Vomiting: Randomized Phase III Trial

Learning Objectives: 1. Compare ramosetron to ondansetron in combination with aprepitant and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic drugs. 2. Discuss the safety of ramosetron in combination with aprepitant and dexamethasone. 3. Discuss subpopulations and conditions that may affect the effectiveness of ramosetron. Background. A combination of serotonin receptor (5-hydroxytryptamine receptor ty...
Society For Translational Oncology

Diagnostics for Invasive Fungal Infections-New and Old

Target audience The enduring activity is intended for health care professionals, particularly physicians, clinical microbiologists, researchers, nurse, nurse practitioners and pharmacists, specializing in prevention and management of fungal infections. Learning objectives Upon completion of the educational activity, participants should be able to: -Discuss the role of new and old diagnostics in the prevention and management of invasive fungal infections Method of Participation In ord...
AKH Inc. Advancing Knowledge in Healthcare

IFIs: Epidemiological Trends, Antifungal Resistance, and Why Antifungal Therapy Fails in Patients with Invasive Mold Infections

Target audience The enduring activity is intended for health care professionals, particularly physicians, clinical microbiologists, researchers, nurse, nurse practitioners and pharmacists, specializing in prevention and management of fungal infections. Learning objectives Upon completion of the educational activity, participants should be able to: -Discuss the role of prophylaxis therapy in patients with invasive fungal infections (IFIs) -Review the emerging data on breakthrough and rel...
AKH Inc. Advancing Knowledge in Healthcare

Standard of Care Treatment - Surgery

•Discuss the current surgical techniques and possibilities of liver surgery •Describe the limits of surgery, complications, and recurrence rate
The France Foundation

Systemic Therapy in Liver-Limited CRC

•Identify the age and gender specific incidence of CRC •Describe the incidence of CRC based on tumor location •Evaluate the stage distribution of CRC at presentation
The France Foundation

Language of Oncology

•Review levels of evidence in oncologic literature •Review clinical trial design and how a trial design can determine the strength & level of evidence its results provide •Discuss methods of assessing response in oncology trials with a focus on the pros and cons of the different methods of response assessment •Discuss how endpoints are analyzed and presented in oncology trials
The France Foundation

The Case for Integration of Locoregional Therapy with Systemic Therapy in Patients with Metastatic Colorectal Cancer (mCRC)

•Evaluate when IO techniques can be proposed in the treatment algorithm •Discuss conceptual arguments to integrate locoregional therapy (radio-embolization) into our current treatment algorithm
The France Foundation

Colorectal Cancer and Colorectal Liver Metastases — Epidemiology

•Identify the age and gender specific incidence of CRC •Describe the incidence of CRC based on tumor location •Evaluate the stage distribution of CRC at presentation
The France Foundation

Diagnosis and Staging of CRC Liver Metastases

•Use imaging to diagnose and stage metastatic liver disease in patients with colorectal cancer
The France Foundation

Ablation vs Surgery: Colon Cancer Liver Metastases

•Discuss the available loco-regional therapies proposed by Interventional Oncology •Evaluate the results of the current literature for ablation, TACE and radio-embolization
The France Foundation

Management of Unresectable Colorectal Carcinoma - Liver Metastases

•Describe standard chemotherapy regimens for unresectable colorectal carcinoma liver metastases (CLM) •Discuss clinical outcomes of systemic treatment for unresectable CLM •Define the role of Interventional Radiology (IR) locoregional therapies (LRTs) in treatment of unresectable CLM •Explain efficacy and safety outcomes of IR LRTs for unresectable CLM
The France Foundation

The Oncologist: A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience

Learning Objectives: 1. Coordinate care of patients with new or progressive breast cancer brain metastases between medical and radiation oncology and neurosurgery in order to preserve neurological function and quality of life. 2. Discuss the ability of a multidisciplinary clinic to provide comprehensive care to patients with breast cancer brain metastases. Background. Breast cancer brain metastasis (BCBM) confers a poor prognosis and is unusual in requiring multidisciplinary care in the ...
Society For Translational Oncology

The Oncologist: Neuroendocrine Carcinoma of the Breast: Current Evidence and Future Perspectives

Learning Objectives: 1. Explain the process for diagnosis of neuroendocrine carcinoma of the breast. 2. Describe the clinical and pathological features of neuroendocrine carcinoma of the breast. Neuroendocrine carcinoma of the breast is considered a rare entity, and for this reason there are no data from prospective clinical trials on its optimal management. Early stage tumors are usually treated with the same strategy used for the other types of invasive breast cancer. Anthracycline- and...
Society For Translational Oncology

The Oncologist: Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis

Learning Objectives: 1. Formulate a plan to follow up patients with lymphomatoid papulosis during an appropriate period in order to diagnose and treat associated lymphomas that decrease the prognosis of LyP. 2. Use identified risk factors to select lymphomatoid papulosis patients who require a close of the breast. Background. Lymphomatoid papulosis (LyP) is classified as an indolent cutaneous lymphoma, but outcome dramatically worsens if LyP is associated with lymphoma. The...
Society For Translational Oncology

Hot Topics in Metastatic Breast Cancer Management: Clinical Advances with CDK4/6 Inhibitors

While the mortality rates for advanced or metastatic breast cancer (MBC) have steadily decreased, in part due to improved treatment options, the 5-year survival rate for MBC remains poor. Fortunately, emerging agents, such as targeted therapies, including the novel class of cyclin-dependent kinase (CDK) 4/6 inhibitors, may improve outcomes for patients with MBC. This CME activity will review the mechanisms of action of new and emerging targeted therapies, as well as evaluate the latest clinica...
Slack Inc.

The Oncologist: Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma

Learning Objectives: 1. Cite the similarities and differences in detecting circulating tumor cells, circulating tumor DNA, and circulating mRNA in melanoma. 2. Discuss the potential for application of circulating tumor products in screening, diagnosis, prognosis, prediction, and genetic or molecular characterization of melanoma. 3. Describe the potential for future research and discovery through circulating tumor products. Circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), an...
Society For Translational Oncology

The Oncologist: Racial Differences in Tobacco Cessation and Treatment Utilization Following Lung Screening: An Examination of the National Lung Screening Trial

Learning Objectives: 1. Identify smoking behaviors among black and white smokers undergoing screening for lung cancer. 2. Describe referral to and uptake of smoking cessation aids and programs. 3. Identify potential barriers to sustained smoking cessation among black and white smokers and compare racial differences in quit activity between the two groups. Background. Black smokers have demonstrated greater lung cancer disease burden and poorer smoking cessation outcomes compared with wh...
Society For Translational Oncology

Combination Strategies in Melanoma Management: What’s New and What’s Next

Melanoma is the sixth most common cancer in the United States and the deadliest form of skin cancer. Although it is often curable if caught early, treatment options are limited for patients with advanced disease. In almost all cases, death is caused by widespread metastatic disease. Fortunately, an improved understanding of the genetic impact of the disease, earlier detection, appropriate staging, and a treatment revolution that has brought new targeted as well as immunotherapies to clinic has...
Slack Inc.

Immune Checkpoint Inhibition for Melanoma Management: When, What, How, and in Whom?

It is estimated that 76,380 new cases of melanoma will be diagnosed in the United Stated in 2017, with approximately 10,130 disease-related deaths. Recent advances in the understanding of the underlying biology of melanoma have resulted in the identification of new novel targets for therapy, resulting in significant improvements to clinical outcomes for patients with advanced disease. As these newer agents, specifically immune checkpoint inhibitors, are incorporated into everyday clinical prac...
Slack Inc.

Toward Precision Medicine for Advanced Melanoma Management: Making the Most of Targeted Agents

The identification and utilization of melanoma specific biomarkers continues to be of importance for diagnosis and prognosis, and the selection of tailored therapy. Common somatic mutations in melanoma have been utilized to predict response to targeted therapy leading to improved clinical outcomes in patients with advanced disease. As targeted treatment strategies continue to evolve, it is essential that clinicians caring for patients with advanced melanoma are familiar with recent clinical ad...
Slack Inc.

Diagnostic and Therapeutic Challenges in Von Willebrand Disease

With the significant variability in the subtypes and clinical manifestations of von Willebrand disease (VWD), diagnosis and treatment of affected individuals are often delayed. The evaluation of hemorrhagic symptoms is challenging for both patients and clinicians because the reporting and interpretation of bleeding symptoms is subjective. Delivery of optimal care is further complicated by the lack of updated management guidelines for VWD. In this activity, the faculty discuss common but cha...
Slack Inc.

Updates in Cardio-Oncology 2018: Challenges and New Frontiers

This course reviews clinically important information regarding the management of cardiac and vascular diseases affecting patients with cancer and cancer survivors. The interactive, practice-based format includes case presentations and state-of-the-art lectures in recent and topical developments in this emerging field. The goal is to improve quality, safety and outcomes for patients within the dynamic and interactive educational experience. The current state of knowledge of common cardiovascula...
Mayo Clinic

Topics in Emergency Medicine Cuban Cruise Conference

◦Toxicology/Poisonings-What's Old and What's New ◦Review the fundamentals of examining and diagnosing the poisoned patient. ◦ Discuss appropriate strategies for managing the common toxicologic emergencies. ◦ Analyze some common and interesting cases in which a poisoned patient presented to the emergency department. ◦ Introduce the listeners to some of the new, and up-and-coming recreational drugs of abuse. ◦Vertigo-I'm So Dizzy, My Head Is Spinnin' ◦Describe the common pres...
Continuing Education, Inc

Rectal Cancer: Updates in Staging and Treatment

This course spans the staging and treatment of patients with rectal cancer, with a focus on new developments and controversies in staging, duration of chemotherapy, and a variety of surgical approaches. Join colleagues from around the Pacific Northwest to learn about the risks and benefits of shorter duration of curative chemotherapy, a major new development in colorectal cancer. Differing staging techniques including controversies about optimal modalities with MRI and endo-rectal ultrasoun...
Virginia Mason

The Oncologist: How Cancers Escape Immune Destruction and Mechanisms of Action for the New Significantly Active Immune Therapies: Helping Non-Immunologists Decipher Recent Advances

Learning Objectives: 1. Explain how cancer can escape normal immune system control. 2. Discuss the ability of new immune therapies to counteract cancers’ ability to escape immune cell mediated death. With the Food and Drug Administration and other worldwide regulatory authorities’ approval of ipilimumab (Yervoy), sipuleucel-T (Provenge), nivolumab (Opdivo), and pembrolizumab (Keytruda), oncologic therapy has now moved into noncancer cell targets within the immune system. For many noni...
Society For Translational Oncology

The Oncologist:Effect of Thyrotropin Suppression Therapy on Bone in Thyroid Cancer Patients

Learning Objectives: 1. Explain the role of thyrotropin suppression therapy in thyroid cancer patients. 2. Discuss implications of thyrotropin suppression therapy on bone in different thyroid cancer population groups. 3. Evaluate the necessity of tailored treatment for groups at risk for skeletal adverse events from thyrotropin suppression therapy. Background. The thyroid cancer incidence is rising. Despite current guidelines, controversy exists regarding the degree and duration of thyr...
Society For Translational Oncology

Clinical and Multidisciplinary Hematology & Oncology: The 15th Annual Review

This course will include a comprehensive update and management strategies of issues in hematologic and oncologic malignancies presenting new disease classification, treatment, and challenging cases. Course topics will focus on key hematologic diseases (dysproteinemias, acute and chronic leukemias, lymphomas), key solid tumors (breast, thoracic, GI, GU), and overlap topics of supportive, ancillary and diagnostic care. The course offers challenging and interactive sessions on pertinent issues in...
Mayo Clinic

The Oncologist: The Rationale for Targeted Therapies and Stereotactic Radiosurgery in the Treatment of Brain Metastases

Learning Objectives: 1. Explain the role of radiosurgery in the treatment of brain metastasis. 2. Describe the rational design and use of targeted therapies in solid malignancy. 3. Cite the current safety and efficacy data on combination targeted therapy and radiosurgery. Brain metastases are the most common intracranial malignancy. Many approaches, including radiation therapy, surgery, and cytotoxic chemotherapy, have been used to treat patients with brain metastases depending on the pa...
Society For Translational Oncology

The Oncologist: Outcomes and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Carcinomas

Learning Objectives: 1. Cite the characteristics and natural history of radioiodine refractory differentiated thyroid carcinomas. 2. Assess outcomes (overall and cancer-specific survivals) and prognostic factors of radioiodine refractory differentiated thyroid carcinomas. 3. Identify patients with the worst prognosis to treat with targeted therapy and patient with indolent disease to follow-up. Background. Outcomes vary among patients with radioiodine refractory (RR) differentiated thyr...
Society For Translational Oncology

The Oncologist: Optimizing the G8 Screening Tool for Older Patients With Cancer: Diagnostic Performance and Validation of a Six-Item Version

Learning Objective: 1. Use the modified G8 screening tool to facilitate selection for a full GA in older cancer patients. Background. A multidimensional geriatric assessment (GA) is recommended in older cancer patients to inventory health problems and tailor treatment decisions accordingly but requires considerable time and human resources. The G8 is among the most sensitive screening tools for selecting patients warranting a full GA but has limited specificity. We sought to develop and v...
Society For Translational Oncology

The Oncologist: Lack of Understanding of Cervical Cancer and Screening Is the Leading Barrier to Screening Uptake in Women at Midlife in Bangladesh: Population-Based Cross-Sectional Survey

Learning Objectives: 1. Discuss the awareness and knowledge of cervical cancer and cervical cancer screening in Bangladesh. 2. Cite the factors and barriers associated with cervical cancer screening uptake. Background. Cervical cancer (CCa) is the second most common cancer among women in Bangladesh. The uptake of CCa screening was less than 10% in areas where screening has been offered, so we investigated the awareness of CCa and CCa screening, and factors associated with women’s prepa...
Society For Translational Oncology

Gastrointestinal Cancers 2018 Current and Emerging Strategies in Multidisciplinary Care: Translating Evidence into Best Practices

This course will focus on case-based and didactic presentations from Mayo Clinic and other international experts in the treatment of the whole spectrum of gastrointestinal (GI) cancers including esophageal, gastric, hepatocellular, pancreatic, small bowel, bile duct, anal and colorectal and gallbladder. The primary goal of this course is to guide practicing physicians on integrating the best and most current evidence into their day-to-day routine care for patients with GI cancers. This cour...
Mayo Clinic

Expert Answers to Frequently Asked Questions About Biosimilars

Topics covered include: Biosimilars vs Small Molecular Generics Biosimilars vs Reference Biologics Regulatory Pathway for Biosimilars Interchangeability of Biosimilars Biosimilars Approved in the US
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

The Identification and Management of Immune-related Adverse Events in Patients with Cancer: Practice Essentials for Emergency Medicine Providers

The incorporation of immunotherapies, especially the immune checkpoint inhibitors, into treatment regimens for patients with cancer, have significantly improved clinical outcomes in these patient populations. The utilization of immune checkpoint inhibitors in cancer therapy are associated with unique immune-related adverse events (irAEs), most commonly manifesting in the skin, gastrointestinal tract, and endocrine system. Patients presenting with irAEs require prompt diagnosis and treatment t...
Slack Inc.

The Oncologist: Association of Macroeconomic Factors With Nonrelapse Mortality After Allogeneic Hematopoietic Cell Transplantation for Adults With Acute Lymphoblastic Leukemia

Learning Objective: 1. Explain how economic factors influence treatment outcome as demonstrated by the case of alloHCT performed for patients with acute lymphoblastic leukemia. Purpose. From a global perspective, the rates of allogeneic hematopoietic cell transplantation (alloHCT) are closely related to the economic status of a country. However, a potential association with outcome has not yet been documented. The goal of this study was to evaluate effects of health care expenditure (HCE)...
Society For Translational Oncology

The Oncologist: Effects of Dexamethasone and Placebo on Symptom Clusters in Advanced Cancer Patients: A Preliminary Report

Learning Objective: 1. Describe the effects of dexamethasone on symptom clusters in patients with advanced cancer. Objective. Advanced cancer patients frequently experience debilitating symptoms that occur in clusters, but few pharmacological studies have targeted symptom clusters. Our objective was to examine the effects of dexamethasone on symptom clusters in patients with advanced cancer. Methods. We reviewed the data from a previous randomized clinical trial to determine the effec...
Society For Translational Oncology

The Oncologist: The European Medicines Agency Review of Bosutinib for the Treatment of Adult Patients With Chronic Myelogenous Leukemia

Learning Objectives: 1. Evaluate the cytogenetic response profile of bosutinib in patients with chronic myelogenous leukemia. 2. Compare the safety profile of bosutinib to other tyrosine kinase inhibitors available to treat patients with chronic myelogenous leukemia. 3. Identify patients with chronic myelogenous leukemia who might benefit from treatment with bosutinib. On March 27, 2013, a conditional marketing authorization valid throughout the European Union was issued for bosutinib (B...
Society For Translational Oncology


Oncology CEUs
VA Omaha

Immune Checkpoint Inhibitors for Advanced Bladder Cancer: Applying Clinical Advances and Elucidating Best Practices

Advances in immunology and the advent of immune checkpoint blockade inhibition for advanced bladder cancer are poised to cause a paradigm shift in the near future. Therefore, it is of utmost importance that oncologists who treat patients with bladder cancer are ready and able to incorporate these agents into practice. In this CME activity, leading oncologists will discuss the latest treatment strategies, clinical advances, and targeted therapies for the treatment of advanced bladder cancer.
Slack Inc.

What's Hot in Melanoma? Highlights from the HemONC Today Melanoma and Cutaneous Malignancies 2017 Meeting

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the management of advanced melanoma has revolutionized the current treatment paradigm. Ongoing research continues to define optimal strategies for the utilization of these therapies; patients who will be provided best benefit; and emerging novel therapies with the potential to further enhance clinical outcomes. This CME activity, recorded at the 2017 HemOnc Today Melanoma and Cutaneo...
Slack Inc.

The Oncologist:Hyperammonemic Encephalopathy Associated With Fibrolamellar Hepatocellular Carcinoma: Case Report, Literature Review, and Proposed Treatment Algorithm

Learning Objectives: 1. Identify paraneoplastic hyperammonemic encephalopathy associated with fibrolamellar hepatocellular carcinoma. 2. Recognize cancer associated hyperammonemic encephalopathy and describe its pathophysiology. 3. Describe treatment algorithm of cancer-associated hyperammonemic encephalopathy. We report a case of a 31-year-old man with metastatic fibrolamellar hepatocellular carcinoma (FLHCC) treated with gemcitabine and oxaliplatin complicated by hyperammonemic encepha...
Society For Translational Oncology

28th Annual Advances in Urology

The 28th Annual Advances in Urology meeting is designed for practicing urologists who are interested in updating their knowledge in the diagnosis, evaluation and management of urologic problems. A distinguished faculty will present advances in the management of urological problems including uro-oncology, sexual function, laparoendoscopic, robotic, minimally invasive surgery, prostate and bladder cancer and reconstruction surgery with a strong emphasis on the technical aspects of various urolo...
USF Health Professions Conferencing Corporation

Newest Oncology Agents: PD-1 Inhibitors - Clinical Information and Patient Management

This is a featured CE activity on the Center for Specialty Pharmacy Education (CSPE) website. CSPE is the educational hub of the National Association of Specialty Pharmacy (NASP). Most CSPE activities include the pathophysiology and clinical therapeutics of various disease states in which specialty pharmacy products and services are provided. CSPE also covers legal, regulatory and operational topics relevant to specialty pharmacy practice. Oncology agents continue to dominate new product de...

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.